• Explore /
  • Poster
  • / Trials in progress: A phase 1, open-label, pharmacokinetic, safety and tolerability study of PF-07265807 (selective TAM kinase inhibitor) alone or with sasanlimab in patients with advanced or metastatic solid tumors.

Trials in progress: A phase 1, open-label, pharmacokinetic, safety and tolerability study of PF-07265807 (selective TAM kinase inhibitor) alone or with sasanlimab in patients with advanced or metastatic solid tumors.

Abstract Poster

Authors

null

Jessica Dreger McDermott

University of Colorado, Aurora, CO;

Jessica Dreger McDermott , Vivek Subbiah , Joseph Thaddeus Beck , Toshihiko Doi , Tomoko Hirohashi , Kim Ingram , Ruifeng Li , James L. Abbruzzese

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04458259

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS270)

DOI

10.1200/JCO.2023.41.4_suppl.TPS270

Abstract #

TPS270

Poster Bd #

P12

Abstract Disclosures

Similar Posters

First Author: Tomoko Hirohashi

First Author: Vivek Subbiah

First Author: Nong Xu

First Author: Manish Sharma